Next Article in Journal
Pharmacokinetics of Haloperidol in Critically Ill Patients: Is There an Association with Inflammation?
Next Article in Special Issue
Formulation and Evaluation of Hybrid Niosomal In Situ Gel for Intravesical Co-Delivery of Curcumin and Gentamicin Sulfate
Previous Article in Journal
Rosinidin Flavonoid Ameliorates Hyperglycemia, Lipid Pathways and Proinflammatory Cytokines in Streptozotocin-Induced Diabetic Rats
Previous Article in Special Issue
Thermoresponsive Chitosan-Grafted-Poly(N-vinylcaprolactam) Microgels via Ionotropic Gelation for Oncological Applications
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 14
Issue 3
10.3390/pharmaceutics14030548
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Mineralizing Gelatin Microparticles as Cell Carrier and Drug Delivery System for siRNA for Bone Tissue Engineering

by
Sandra Hinkelmann
1,
Alexandra H. Springwald
1,
Sabine Schulze
2,
Ute Hempel
3,
Franziska Mitrach
1,
Christian Wölk
1,
Michael C. Hacker
1,4 and
Michaela Schulz-Siegmund
1,*
1
Pharmaceutical Technology, Faculty of Medicine, Institute of Pharmacy, University of Leipzig, Eilenburger Straße 15A, 04317 Leipzig, Germany
2
Joint and Soft Tissue Research, Centre for Translational Bone, Faculty of Medicine, TU Dresden, Fiedlerstraße 34, 01307 Dresden, Germany
3
Institute of Physiological Chemistry, TU Dresden, Fiedlerstraße 42, 01307 Dresden, Germany
4
Institute of Pharmaceutics and Biopharmaceutics, Heinrich Heine University, Universitätsstr. 1, 40225 Düsseldorf, Germany
*
Author to whom correspondence should be addressed.
Pharmaceutics 2022, 14(3), 548; https://doi.org/10.3390/pharmaceutics14030548
Submission received: 21 January 2022 / Revised: 24 February 2022 / Accepted: 25 February 2022 / Published: 28 February 2022
(This article belongs to the Special Issue Biopolymer Micro/Nanogel Particles as Smart Drug Delivery and Theranostic Systems)
Browse Figures
Versions Notes

Abstract

:
The local release of complexed siRNA from biomaterials opens precisely targeted therapeutic options. In this study, complexed siRNA was loaded to gelatin microparticles cross-linked (cGM) with an anhydride-containing oligomer (oPNMA). We aggregated these siRNA-loaded cGM with human mesenchymal stem cells (hMSC) to microtissues and stimulated them with osteogenic supplements. An efficient knockdown of chordin, a BMP-2 antagonist, caused a remarkably increased alkaline phosphatase (ALP) activity in the microtissues. cGM, as a component of microtissues, mineralized in a differentiation medium within 8–9 days, both in the presence and in the absence of cells. In order to investigate the effects of our pre-differentiated and chordin-silenced microtissues on bone homeostasis, we simulated in vivo conditions in an unstimulated co-culture system of hMSC and human peripheral blood mononuclear cells (hPBMC). We found enhanced ALP activity and osteoprotegerin (OPG) secretion in the model system compared to control microtissues. Our results suggest osteoanabolic effects of pre-differentiated and chordin-silenced microtissues.

Graphical Abstract

1. Introduction

Since its discovery in 1998, the development of RNA interference (RNAi) strategies in regenerative medicine have progressed rapidly [1,2,3,4,5]. The RNAi mechanism enables a targeted and post-transcriptional silencing of gene expression by small interfering RNA (siRNA) and microRNA (miRNA) [6,7,8]. Both can bind and induce the degradation of complementary messenger RNA (mRNA) by activating the RNA-induced silencing complex (RISC) [9]. Previous studies have shown that RNAi can improve bone regeneration in vitro [10,11,12,13] and in vivo [14,15]. While the use of siRNA allows a very specific downregulation of proteins that control cell differentiation, miRNAs usually have several targets, with a multitude of consequences to cellular processes. Nonetheless, the application of siRNA is limited by natural barriers, such as nucleases present in the tissue able to quickly degrade naked siRNA and an inefficient cellular uptake due to the anionic character and large molecular weight of siRNA [16,17,18]. To overcome these limitations, a broad variety of transfection reagents (e.g., cationic polymers, cationic lipid composites, and peptides) have been developed that protect the siRNA by complex formation and enable cellular uptake as well as intracellular release [18,19]. Nevertheless, the type of application is still decisive for the biological outcome of a silencing strategy. While systemic application of siRNA complexes often leads to accumulation in the liver and provides immunostimulatory activity, the local application may increase the therapeutic effect [19,20]. Using siRNA-loaded hydrogels that mimic the extracellular matrix and present siRNA to co-encapsulated or attaching cells could be an interesting application strategy in regenerative medicine [21,22,23,24].
In this project, we focused on an innovative approach for the regeneration of bone tissue, to meet the clinical need for strategies to replace autologous bone grafts. Although the transplantation of autologous bone is still the gold standard in bone repair, the available amount is limited, depending on the existing bone structure and underlying diseases of the patient [25]. However, we think that the use of stem cells instead of whole tissue fragments may suffice to stimulate regeneration in defective bone tissue [26,27]. For this reason, we aggregated human mesenchymal stem cells (hMSC) with siRNA delivering cross-linked gelatin microparticles (cGM) to form microtissues for the treatment of bone defects. Microtissues were additionally stimulated with osteogenic supplements. These 3D constructs mimic a biosimilar microenvironment with cell–cell and cell–matrix contacts. The microparticles provide a substrate for cell adhesion and improve oxygen and nutrient supply in the microtissues [28,29]. In order to enhance bone regeneration by siRNA, we silenced chordin, an antagonist of the bone morphogenetic protein 2 (BMP-2) [30,31], and followed the hypothesis that the silencing of chordin in combination with BMP-2 supplementation may enhance osteogenic differentiation and accelerate mineralization in osteogenic cultures [10,13,32,33,34]. These microtissues may be applied similarly as autologous bone grafts.
In a previous study, we reported on non-mineralizing gelatin microparticles and showed improved mineralization of the chordin siRNA-releasing microparticles [34]. Here, we changed the protocol to greatly increase the cross-linking degree of cGMs from 37.2% to 50.7%. As a decisive consequence of the stronger cross-linking reaction between the anhydride-containing (oPNMA) and amino groups in gelatin, the number of carboxylate groups in the microparticles is concomitantly increased. The increased anionic charge density is expected to improve calcium affinity, which has been described as a nucleation center for mineral formation [35]. Via partial reaction of oPNMA with N, N-diethylethylenediamine (DEED), we derivatized the cross-linker with non-reactive tertiary amine functionalities. The changed electrostatic properties are designed to stabilize complexed siRNA and make it available for cellular uptake. This study aimed to investigate if the stronger cross-linking affects hydroxyapatite (HA) formation as the mineral phase of bone tissue in the presence and absence of cells. Further to this, we investigated if the higher cross-linking degree had an influence on the silencing efficiency of the chordin siRNA loaded to the cGM. Finally, we tested the effects of microtissues on bone homeostasis in a co-culture model of hMSC and human peripheral blood mononuclear cells (hPBMC). Here, we were able to show a high silencing effect due to the changed electrostatic properties of the particle surface in contrast to the previously published data [34].

2. Materials and Methods

2.1. Particle Fabrication

Gelatin microparticles (GM) cross-linked with the pre-derivatized oligomeric cross-linker oligo (pentaerythritol diacrylate monostearate (P)-co-N-isopropylacrylamide(N)-co-maleic anhydride (MA)) (oPNMA-7.5+DEED) were fabricated according to published protocols [34,36,37]. Compared to the protocol published before [34], cross-linking degree of the cGM was increased by addition of triethylamine (TEA). Briefly, 1 g of GM was dispersed in 2 mL of acetone before the pre-derivatized reaction solution containing oPNMA-7.5+DEED as cross-linker, 2 mL of the base triethylamine (TEA), and 10 mL of water were added, stirred for 4 h, then washed and dried as described previously [34]. The particles were characterized as described in the prior publication [34].

2.2. Preparation of siRNA-Loaded Microparticles

For loading of the microparticles, 703.13 ng chordin siRNA (Dharmacon, Lafayette, CO, USA) and 15.78 µL Lipofectamine® RNAiMAX (Thermo Fisher Scientific™, Schwerte, Germany) were complexed in 24 µL, added to 3 mg dried cGM, vortexed and incubated at 4 °C for 30 min [34]. Subsequently, loaded cGM were resuspended in Opti-MEM™ (Thermo Fisher Scientific™, Schwerte, Germany) supplemented with 10% FBS. The final suspension contained 0.064 mg cGM loaded with 15 ng siRNA/100 µL. As control, cGM were loaded with Opti-MEM™ only (ctr: non-treated control) or All Stars Negative Control (Qiagen, Hilden, Germany) siRNA (nc: non-coding control).

2.3. Microtissues

Assembling of cells and particles to microtissues followed a previously described protocol [34]. Briefly, hMSC (Lonza, Basel, Switzerland) were cultivated in DMEM low glucose (Sigma Aldrich, Seelze, Germany), 10% (v/v) fetal bovine serum albumin (FBS, Biochrome, Berlin, Germany), 1% amino acids and antibiotics and detached the cells with Trypsin/EDTA (Sigma Aldrich, Seelze, Germany). We added 100 µL of cell suspension (105 cells ml−1) to 100 µL of cGM suspension (0.64 mg ml−1) in Opti-MEM™ with 10% FBS per well of a low adhesion 96-well plate (Spheroid microplate, Corning, NY, USA). After 24 h, the medium was changed to osteogenic medium (OM) based on DMEM, 10% (v/v) FBS, 100 ng/mL Dexamethasone (Sigma Aldrich, Seelze, Germany), 50 µg/mL ascorbic acid (Sigma Aldrich, Seelze, Germany), 10 mM β-Glycerophosphate disodium salt hydrate (Sigma Aldrich, Seelze, Germany) with (OM+BMP-2)/without (OM) 100 ng/mL bone morphogenetic protein (BMP-2, R&D Systems, Wiesbaden, Germany). Medium was changed partially by exchanging 200 µL of culture medium twice for three times a week in order to keep cGM/hMSC and microtissues in the well.

2.4. Gene Expression Analyses

RNA isolation, cDNA synthesis, and PCR were performed as previously described [34]. Used TaqMan™ gene expression assays are shown in Table 1. 60S acidic ribosomal protein P0 (RPLP0) served as a housekeeping gene [38].

2.5. Osteogenic Differentiation of hMSC in Microtissues

Alkaline phosphatase (ALP) activity and calcium content were determined and normalized to deoxyribonucleic acid (DNA) content in the microtissues as previously published [34]. For calculation of Ca/P-ratio, phosphate concentration was measured with a phosphorus quantification kit (Greiner Diagnostic Group, Bahlingen, Germany). DNA quantity was determined for normalization of ALP activity and calcium content. DNA quantity in microtissues was measured in a Plate Reader Synergy H1 (BioTek, Bad Friedrichshall, Germany) using Quant-iT™ PicoGreen™ dsDNA (Invitrogen™, Darmstadt, Germany) following a previously described protocol [10,11]. A standard curve of increasing DNA dilutions (Invitrogen™, Darmstadt, Germany) in a range of 0.001–10 µg/mL was used for the quantification of unknown samples.

2.6. Cryosectioning

Samples were washed with warm PBS (37 °C), fixed with 10% paraformaldehyde (PFA) for 1 h at RT. Dehydration of samples was conducted with 30% sucrose for 24 h (4 °C). Then, samples were embedded in Tissue Freezing Medium (Leica, Wetzlar, Germany) at −80 °C for 15 min. Frozen sections of 10–20 µm thickness were prepared by Cryostat (Leica, Wetzlar, Germany).

2.7. Microscopy

Washed and PFA fixed samples were stained with OsteoImage (Lonza, Basel, Switzerland) for visualization of hydroxyapatite (HA), as reported before [34], according to the manual. Staining with 1 µL 4′,6-diamidino-2-phenylindole (DAPI) and 25 µL Alexa Fluor™ 568 phalloidin (Thermo Fisher Scientific™, Schwerte, Germany) was performed to analyze cell morphology. Alizarin Red staining was performed to visualize matrix formation and mineralization in cryosections as reported before [34]. A confocal microscope Leica TCS SP8 and LAS X software (Leica, Wetzlar, Germany) were used for imaging.

2.8. Microtissues in a Supplement-Free Co-Culture System of hMSC and PBMC

Peripheral blood mononuclear cells (PBMC) and hMSC were directly co-cultured with microtissues on an osteoblast-derived and decellularized extracellular matrix generated by SaOS-2 cells. The experimental procedure followed previously described protocols [39,40]. In brief, microtissues were assembled with hMSC as described above and incubated for 7 days in OM or OM+BMP-2. PBMC were isolated from donated buffy coats by Ficoll gradient centrifugation and seeded (1.5 × 105/cm2) on the matrix in α-MEM (Sigma Aldrich, Seelze, Germany) with 20% heat-inactivated FBS, 1% P/S, and 2 mM glutamine (Sigma Aldrich, Seelze, Germany). hMSC suspension (2500/cm2) was added after 2 h and pre-differentiated microtissues after another 30 min. Two microtissues were placed at the edges of one well. The supernatants were collected after 3, 6, 10, and 14 days and analyzed with Human Osteoprotegerin DuoSet Enzyme-linked immunosorbent assay (ELISA, R&D Systems, Wiesbaden, Germany). ALP and tartrate-resistant acid phosphatase (TRAP) were analyzed after 14 days as previously described [40]. Adsorption values were calculated concerning non-treated cells in OM and set to 1 as control.

2.9. Statistics

One-way ANOVA with Tukey’s post hoc test was performed using GraphPad Prism version 9.2.0 for Windows (GraphPad Software, La Jolla California, CA, USA). Statistically significant differences between groups (p < 0.05) are indicated by (*), (#), or (§).

3. Results

3.1. Characterization of Mineralizing oPNMA-7.5+DEED Cross-Linked Gelatin Microparticles

oPNMA-7.5+DEED cGM were obtained as a free-flowing, dry powder with a cross-linking degree of 50.7% and an average particle size of D [4,3] = 79.15 ± 10.68 µm in the dry state (Table 2). For PBS uptake, a factor of 10.8, representing the fold increase in wet weight over dry weight, was calculated. The average particle size of particles swollen in PBS overnight was D [4,3] = 137.67 ± 18.77 µm.

3.2. Silencing Efficiency of cGM-Released siRNA

The effect of siRNA released from cGM in microtissues was investigated in osteogenic media with or without BMP-2 by gene expression analysis after 4 days (Figure 1). We detected effective chordin silencing in both groups with statistically significant differences between chordin siRNA and non-treated or non-coding control. Additionally, a significant increase in ALP gene expression was measured already after 4 days when chordin siRNA was loaded to cGM in microtissues. This effect was enhanced when samples were stimulated with BMP-2.
In order to analyze downstream effects of chordin silencing in microtissues, ALP activity was measured after 7 days, and mineralization was quantified after 14 and 21 days. We detected a significantly increased ALP activity in microtissues when chordin siRNA was loaded to cGM (Figure 2a), which is in accordance with gene expression data. By BMP-2 stimulation, this effect was enhanced in comparison to non-stimulated or non-coding siRNA samples. However, we could not find significant differences in calcium quantities between chordin-silenced and non-silenced samples (Figure 2b and Figure S1). Nevertheless, a distinct increase in the amount of calcium was observed between 14 and 21 days in BMP-2-stimulated and non-stimulated samples. In order to analyze the proliferation in microtissues over 21 days, DNA content was determined on days 7, 14, and 21. The proliferation rate of hMSC in BMP-2-stimulated microtissues was strongly decreased, irrespective of chordin silencing (Figure 3). In the samples without BMP-2 stimulation, a linear increase in the DNA content could be measured in all groups (Figure 3 and Table 3).

3.3. Differences during Mineralization after Chordin Silencing

We also analyzed the morphology of microtissues to obtain a better understanding of the mineral quality. OsteoImage staining (green) indicated the presence of hydroxyapatite (HA) in the mineralized cGM (Figure 4). The fluorescence signal in chordin-silenced microtissues was slightly increased in comparison to the non-coding or non-treated controls. BMP-2-stimulated microtissues generally showed a higher HA attributable fluorescence intensity than samples cultivated without BMP-2. In the chordin-silenced microtissues cultivated without BMP-2 and in all BMP-2-stimulated groups, we found extensive HA formation in the interspace of agglomerated cGMs (highlighted by white arrows). When chordin was silenced and microtissues were cultured with BMP-2, the HA-attributed fluorescence signal was even detectable at the surface of the surrounding well.
Alizarin red staining (ARS) of cryosections was carried out to visualize mineralized extracellular matrix components in general (Figure 5a) and OsteoImage staining was performed for the identification of HA structures (Figure 5b). Obvious differences in the surface structure of the cGM could be recognized in the cryosections. Microparticles in chordin-silenced microtissues showed a smooth structure at the cross-section area in the inner part, whereas rough, dotted HA structures were visible in the non-coding and to a lesser degree in the non-treated controls.
Mineralization in the microparticles apparently started from two directions in all groups. In the early mineralization stages, ARS- and OsteoImage-positive structures were found in the inner core and the outer layer (Figure 6). In later stages of mineralization, minerals were detected throughout the entire cGM. In order to analyze mineralization quality, we determined the calcium–phosphate ratio in the mineralized samples (Figure 7). Chordin-silenced microtissues, which were stimulated with BMP-2 showed a close approximation to the stoichiometric value (1.67) of pure HA at both measuring points. The control groups showed values with a tendency to higher values than 1.67. However, the differences between the groups were not significant. For a better understanding of mineralization in cGM, a defined amount of cGM was placed in a spheroid microwell in the absence of cells and identically cultivated to the treatment of microtissues with cells. We observed mineralization of particles even in the absence of cells in the differentiation medium (Supplementary Materials Figure S2).

3.4. Pre-Differentiated Microtissues in a Supplement-Free Co-Culture of hPBMC and hMSC

For first investigations regarding the suitability of microtissues as a therapeutic approach for bone regeneration, we added pre-differentiated microtissues (7 days in OM or OM+BMP-2) to a co-culture system of undifferentiated hMSC and PBMC [39,40]. In preparation for the supplement-free co-culture of osteoblasts and osteoclasts, well plates were cultivated with SaOS-2 cells for ~25 days in an osteogenic medium to generate a homogeneous layer of the extracellular matrix with a reservoir of bone matrix mediators. That matrix was decellularized before hMSC and PBMC were seeded and cultured in basic culture medium without differentiating supplements. Two microtissues were placed at the edge of each well and co-cultured with hMSC and hPBMC for 14 days to determine the effects of microtissues on osteogenic and osteoclastic differentiation (Figure 8).
Co-cultures with chordin-silenced microtissues pre-treated with and without BMP-2 showed significantly higher ALP activities compared to the non-treated and non-coding control. However, we could not find any differences in TRAP activity. In order to determine the interaction of osteoblasts and osteoclasts, osteoprotegerin (OPG) as a key player in the differentiation of osteoclasts was determined. OPG, secreted by osteoblasts, is a soluble receptor and an inhibitor of receptor activator of nuclear factor kappa B ligand (RANKL) [41,42]. Significantly increased OPG concentrations were found in the supernatant of the co-culture with silenced microtissues pre-treated with BMP-2 compared to all other groups on days 10 and 14 (Figure 9). Without BMP-2, the effect was only detectable between the non-coding control and the chordin-silenced group.

4. Discussion

This study continued a former study [34] where we established the microtissue formation and obtained the first hints that silencing via cGM is promising. The important difference to the previously published work is the clearly higher degree of cross-linking of the investigated cGMs. The degree of cross-linking was 50% compared to 37% in the former study as a result of the addition of TEA during the cross-linking reaction. That characteristic most probably increased the charge density at/in the GM, with negatively charged carboxy groups originating from the aminolyzed maleic anhydrides (MA) and positively charged amino groups from the partial DEED derivatization of the MA groups.
We developed stable microtissues from the combination of hMSC and siRNA-loaded microparticles, which in the future could be implanted directly into bone defects via minimally invasive surgery or embedded in a hydrogel or a fiber mesh. Our system offers the basis for a multi-unit system with options to modify the biophysical and biochemical properties [43] of cGM, the choice of siRNA target and complexation, and finally the cell type and cell pre-treatment. We could show in this study, that an apparently small difference as an increase in the cross-linking degree results in clearly improved silencing and mineral composition.

4.1. Effective Silencing by cGM-Released siRNA

It has already been described that microparticles incorporated in cell aggregates could improve the supply of nutrients and oxygen in the inner core and, at the same time, also release active ingredients in order to affect surrounding cells locally [21,28,29,43,44,45,46]. In our study, we could successfully demonstrate that the synthesized cGM serves as a cell carrier providing structural support and nutrient supply and as a drug delivery biomaterial for siRNA in microtissues. The local presentation of chordin siRNA to hMSC in the microtissues led to a chordin knockdown of approximately 85% compared to the non-treated and non-coding control. Non-complexed (naked) siRNA was not considered as a control as we did not find any silencing effects in former studies in accordance with the literature [17,18].
We believe that electrostatic interaction between the positively charged siRNA complexes and negatively charged carboxyl groups present in gelatin and introduced by the cross-linker are involved to effectively present and deliver the complexed siRNA directly to adhering cells [34]. Stronger cross-linking as determined in this study compared to our previous study probably resulted in higher negative charge density in the microparticles, which might have improved siRNA binding, release, and presentation to the adhering cells. The influence of the DEED modification of the cross-linker, however, needs further systematic investigation.
The combination of chordin siRNA and BMP-2 stimulation led to significantly elevated ALP expression and enzyme activity, which is a relevant marker for in vivo bone formation in stem cells [47]. The cross-linked microparticles mineralized in an osteogenic medium after 8–9 days, both in the presence and in the absence of cells. The ability for mineralization and the strong silencing effect clearly distinguishes the here presented cGM from previously published data [34]. Compared to the former study, cGM showed a significantly higher degree of cross-linking and higher incorporation of the cross-linker oPNMA+DEED in the presence of TEA as base. The existing carboxyl groups in gelatin and the incorporated carboxyl groups of the cross-linker enhanced the negative charges in the microparticles. These presumably support calcium phosphate nucleation, either directly or via the adsorption of mineralizing osteogenic proteins, such as osteopontin or bone sialoprotein [35]. In contrast to our previous study [34] where we used cGM that did not mineralize in the absence of cells, we could not measure any differences in the calcium content in the different groups after 14 or 21 days. Calcium content, however, was strongly increased in all groups compared to the previous study with cGM of a lower cross-linking degree [34]. This result supports our hypothesis that the electrostatic conditions associated with the amount of incorporated cross-linker are strongly related to the intensity and rate of mineralization.

4.2. Chordin Silencing Influences Mineral Composition in Microtissues

The ability of the cGM for biomineralization could positively influence osteogenic differentiation [48,49,50]. In cell-independent mineralization, as well as the availability of calcium and phosphate, the chemical composition of the environment such as pH and CO2, plays a decisive role regarding the morphology, water content, element composition, structure, and particle size of precipitated minerals [51,52,53]. During the biologically controlled mineralization, cells also influence nucleation, growth, morphology, and the final location of the deposited mineral [51].
In chordin-silenced and BMP-2-stimulated microtissues, mineralized cGM appeared morphologically different from non-coding siRNA and non-treated cGM controls. The surface of the particles was smoother, possibly indicating nano-structured mineral in contrast to micron-structured mineral formation in controls. This may be explained by chordin silencing that led to increased bioavailability of endogenously produced and exogenously supplemented BMP-2 in hMSC, which led to a downstream increase in ALP expression and enhanced osteogenic differentiation [10,32,33]. Li et al. also reported differences in mineral structure depending on ALP activity for chitosan hydrogels [54]. They described that precipitated pure glycerophosphate shows rough micron-scaled structures, whereas mineral formation by ALP-cleaved glycerophosphate showed nano-scaled structures. Similarly, Öfkeli et al. reported gelatin hydrogel biomineralization with simulated body fluid and also observed micron-sized HA-particles in the gels [55]. We therefore speculate that ALP may play a special role in our system. The enzyme catalyzes the hydrolysis of organic phosphate to release free inorganic phosphate providing the chemical precursors for mineral deposition [53,56,57]. In contrast to former studies [10,32], we did not find a reduced proliferation rate in chordin-silenced samples compared to the non-treated control.
We assume that due to the mineralization of the particles, the biomechanical properties of the cGM also changed during culture. It is known from the literature that the shape, stiffness, and geometry of microparticles could influence the fate and functional behavior of cells [58]. However, an analysis was beyond the scope of this paper. A synergistic effect of biochemical signaling of the cells, the associated increased ALP activity, and the influence of the material itself is possible.

4.3. Microtissues in a Supplement-Free Co-Culture of hMSC and PBMC

In order to mimic the influence of pre-differentiated microtissues on bone tissue formation, we used an established in vitro co-culture system of osteoblasts and osteoclasts [39,40]. Chordin-silenced and BMP-2-treated microtissues stimulated the differentiation of stem cells in the co-culture, which would be indicated by enhanced ALP activity. Recent studies have shown that the gene expression of the osteoblast transcription factors Runx2 and osterix are dependent on ALP activity and thereby responsible for osteoprogenitor differentiation [59]. In addition, ALP catalyzes the dephosphorylation of phosphorylated osteopontin (p-OPN) [60]. Furthermore, the chordin-silenced and BMP-2-stimulated microtissues led to upregulated OPG concentrations in the co-culture. OPG is secreted by osteoblasts whether or not osteoclasts are present [61] and represents, together with receptor activator of nuclear factor (NF-kappaB) ligand (RANKL), an important paracrine regulator of osteoclastogenesis. Osteoblast-produced factors could directly activate (macrophage colony-stimulating factor/M-CSF, RANKL) [62,63] or inhibit (OPG) [41,42] the osteoclastogenesis.
The presence of high OPG level in the co-culture inhibits RANKL-binding to its receptor and therefore the maturation of PBMC to osteoclasts. The measurable TRAP activity and microscopic images in a control plate (data not shown) indicate the presence of a low number of osteoclasts in the co-culture.
Nevertheless, there are some unanswered questions that we have not yet been able to clarify.
Could the differently pre-treated microtissues alone stimulate the undifferentiated stem cells to the osteogenic lineage, which could be shown by an increased ALP and OPG? Birmingham et al. reported the differentiation of stem cells only by the regulation of osteoblasts or osteocytes [64]. The paper described that higher differentiated osteocytes accelerated the differentiation compared to less-differentiated osteoblasts, which supports our hypothesis.
Could the particles in the differentiated microtissues adsorb BMP-2 and thus influence the unstimulated hMSC? It has been shown that BMP-2 could induce increased levels of OPG in osteoblast-like cells [61,65].
Are the measured ALP and OPG levels caused by the microtissues or by the stimulated hMSC in the co-culture? An interesting study from Granero-Moltό et al. showed that transplanted MSCs contribute to fracture healing by expressing BMP-2 [66], which could also be an explanation for the increasing ALP and OPG level in our results. Due to the complex interrelationships, we cannot explain which paracrine effects trigger the stimulation of the stem cells, yet. However, we suspect that our results reflect synergistic effects.
Several studies described problems due to interactions of positively charged nucleic acid delivery systems for gene therapy with blood components [67], negative effects to the immunoglobulin production [68], or cytotoxicity [69,70]. We suppose that the release of the siRNA to the microtissue forming cells in vitro provides very defined local effects that at the time of implantation, are not expected to induce any side effects via siRNA. The transfection with chordin siRNA and stimulation with BMP-2 lead to a faster differentiation of hMSC in the microtissues. These microtissues influence cells in their direct vicinity. Nevertheless, for clarity concerning therapeutic effects as well as possible side effects, in vivo experiments are needed.
The microtissues are designed to be introduced into a bone defect in vivo either directly or via a matrix. In our in vitro studies, the microtissues remained stable up to the maximum duration of the experiment of 28 days. In any case, this time seems to be sufficient to stimulate the surrounding cells and to serve as a starting point for mineralization, as we have shown here and in the previous work [32]. Bone is a highly dynamic tissue that is constantly being remodeled by osteoblasts and osteoclasts. We suspect that the mineralized microtissues will be replaced by the body’s own tissue after several weeks to months [71].

5. Conclusions

We presented mineralizing cGM, which form microtissues with hMSCs. Via siRNA loading of cGM, we showed highly efficient silencing of chordin and, in consequence, strongly increased ALP activity, supported by supplementation with BMP-2. Chordin-silenced microtissues precultured with BMP-2 were able to mediate osteoanabolic effects in co-cultures of hMSC and hPBMC. This may be an indication that microtissues from autologous hMSC may be able to mimic bone autografts in bone defects.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/pharmaceutics14030548/s1, Figure S1: Representative images (phase contrast microscopy) of microtissue mineralization with and without siRNA or/and BMP-2; Figure S2: Phase contrast images of cGM control wells after 7, 14, and 21 days in an osteogenic medium in absence of cells.

Author Contributions

Conceptualization, S.H., A.H.S., C.W., M.C.H. and M.S.-S.; data curation, S.S. and F.M.; funding acquisition, M.C.H. and M.S.-S.; investigation, S.H. and A.H.S.; methodology, S.S. and U.H.; supervision, M.C.H. and M.S.-S.; visualization, S.H.; writing—original draft, S.H. and A.H.S.; writing—review and editing, C.W., M.C.H. and M.S.-S. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation)-project number 59307082-TRR67 (subproject A1; B1; B5) and the Saxonian State Ministry for Science and the Arts (SMWK, 221507013). We acknowledge support from Leipzig University for Open Access Publishing.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

On request, the raw data can be sent by email.

Acknowledgments

We would like to thank Hermann Kalwa from Rudolf-Boehm-Institute for Pharmacology and Toxicology, University of Leipzig for supporting microscopic imaging and Ulf Anderegg from the University Dermatology Clinic in Leipzig for providing the cryotome. We thank Annett Starke from the Pharmaceutical Technology, University of Leipzig for the laboratory support.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

  1. Fire, A.; Xu, S.; Montgomery, M.K.; Kostas, S.A.; Driver, S.E.; Mello, C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391, 806–811. [Google Scholar] [CrossRef] [PubMed]
  2. Yu, T.; Wang, H.; Zhang, Y.; Wang, X.; Han, B. The Delivery of RNA-Interference Therapies Based on Engineered Hydrogels for Bone Tissue Regeneration. Front. Bioeng. Biotechnol. 2020, 8, 445. [Google Scholar] [CrossRef]
  3. Carballo-Pedrares, N.; Fuentes-Boquete, I.; Díaz-Prado, S.; Rey-Rico, A. Hydrogel-Based Localized Nonviral Gene Delivery in Regenerative Medicine Approaches—An Overview. Pharmaceutics 2020, 12, 752. [Google Scholar] [CrossRef]
  4. Brüggenwirth, I.M.A.; Martins, P.N. RNA interference therapeutics in organ transplantation: The dawn of a new era. Am. J. Transpl. 2020, 20, 931–941. [Google Scholar] [CrossRef] [PubMed]
  5. Damiati, L.A.; El-Messeiry, S. An Overview of RNA-Based Scaffolds for Osteogenesis. Front. Mol. Biosci. 2021, 8, 454. [Google Scholar] [CrossRef]
  6. Elbashir, S.M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411, 494–498. [Google Scholar] [CrossRef]
  7. McCaffrey, A.P.; Meuse, L.; Pham, T.-T.T.; Conklin, D.S.; Hannon, G.J.; Kay, M.A. RNA interference in adult mice. Nature 2002, 418, 38–39. [Google Scholar] [CrossRef]
  8. Wilson, R.C.; Doudna, J.A. Molecular Mechanisms of RNA Interference. Annu. Rev. Biophys. 2013, 42, 217–239. [Google Scholar] [CrossRef] [Green Version]
  9. Tijsterman, M.; Plasterk, R.H. Dicers at RISC. Cell 2004, 117, 1–3. [Google Scholar] [CrossRef] [Green Version]
  10. Schneider, H.; Sedaghati, B.; Naumann, A.; Hacker, M.C.; Schulz-Siegmund, M. Gene Silencing of Chordin Improves BMP-2 Effects on Osteogenic Differentiation of Human Adipose Tissue-Derived Stromal Cells. Tissue Eng. Part A 2014, 20, 335–345. [Google Scholar] [CrossRef]
  11. Sedaghati, B.; Jahroomishirazi, R.; Starke, A.; Hacker, M.C.; Schulz-Siegmund, M. Rat Osteosarcoma Cells as a Therapeutic Target Model for Osteoregeneration via Sclerostin Knockdown. Cells Tissues Organs 2016, 201, 366–379. [Google Scholar] [CrossRef]
  12. Zhang, J.; Tu, Q.; Bonewald, L.F.; He, X.; Stein, G.; Lian, J.; Chen, J. Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1. J. Bone Miner. Res. 2011, 26, 1953–1963. [Google Scholar] [CrossRef] [Green Version]
  13. Wang, C.; Xiao, F.; Gan, Y.; Yuan, W.; Zhai, Z.; Jin, T.; Chen, X.; Zhang, X. Improving Bone Regeneration Using Chordin siRNA Delivered by pH-Responsive and Non-Toxic Polyspermine Imidazole-4,5-Imine. Cell Physiol. Biochem. 2018, 46, 133–147. [Google Scholar] [CrossRef]
  14. Wang, Y.; Malcolm, D.W.; Benoit, D.S. Controlled and sustained delivery of siRNA/NPs from hydrogels expedites bone fracture healing. Biomaterials 2017, 139, 127–138. [Google Scholar] [CrossRef]
  15. Li, Y.; Fan, L.; Liu, S.; Liu, W.; Zhang, H.; Zhou, T.; Wu, D.; Yang, P.; Shen, L.; Chen, J.; et al. The promotion of bone regeneration through positive regulation of angiogenic–osteogenic coupling using microRNA-26a. Biomaterials 2013, 34, 5048–5058. [Google Scholar] [CrossRef]
  16. Liu, H.; Li, Y.; Mozhi, A.; Zhang, L.; Liu, Y.; Xu, X.; Xing, J.; Liang, X.; Ma, G.; Yang, J.; et al. SiRNA-phospholipid conjugates for gene and drug delivery in cancer treatment. Biomaterials 2014, 35, 6519–6533. [Google Scholar] [CrossRef]
  17. Mitrach, F.; Schmid, M.; Toussaint, M.; Dukic-Stefanovic, S.; Deuther-Conrad, W.; Franke, H.; Ewe, A.; Aigner, A.; Wölk, C.; Brust, P.; et al. Amphiphilic Anionic Oligomer-Stabilized Calcium Phosphate Nanoparticles with Prospects in siRNA Delivery via Convection-Enhanced Delivery. Pharmaceutics 2022, 14, 326. [Google Scholar] [CrossRef]
  18. Whitehead, K.A.; Langer, R.; Anderson, D.G. Knocking down barriers: Advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8, 129–138. [Google Scholar] [CrossRef]
  19. Hu, B.; Zhong, L.; Weng, Y.; Peng, L.; Huang, Y.; Zhao, Y.; Liang, X.-J. Therapeutic siRNA: State of the art. Sig. Transduct. Target. Ther. 2020, 5, 101. [Google Scholar] [CrossRef]
  20. Jackson, A.L.; Linsley, P.S. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. 2010, 9, 57–67. [Google Scholar] [CrossRef]
  21. McMillan, A.; Nguyen, M.K.; Huynh, C.T.; Sarett, S.M.; Ge, P.; Chetverikova, M.; Nguyen, K.; Grosh, D.; Duvall, C.L.; Alsberg, E. Hydrogel microspheres for spatiotemporally controlled delivery of RNA and silencing gene expression within scaffold-free tissue engineered constructs. Acta Biomater. 2021, 124, 315–326. [Google Scholar] [CrossRef]
  22. Schwabe, K.; Ewe, A.; Kohn, C.; Loth, T.; Aigner, A.; Hacker, M.C.; Schulz-Siegmund, M. Sustained delivery of siRNA poly- and lipopolyplexes from porous macromer-crosslinked gelatin gels. Int. J. Pharm. 2017, 526, 178–187. [Google Scholar] [CrossRef]
  23. Kim, S.; Fan, J.; Lee, C.-S.; Chen, C.; Lee, M. Sulfonate Hydrogel–siRNA Conjugate Facilitates Osteogenic Differentiation of Mesenchymal Stem Cells by Controlled Gene Silencing and Activation of BMP Signaling. ACS Appl. Bio Mater. 2021, 4, 5189–5200. [Google Scholar] [CrossRef]
  24. Yin, N.; Tan, X.; Liu, H.; He, F.; Ding, N.; Gou, J.; Yin, T.; He, H.; Zhang, Y.; Tang, X. A novel indomethacin/methotrexate/MMP-9 siRNA in situ hydrogel with dual effects of anti-inflammatory activity and reversal of cartilage disruption for the synergistic treatment of rheumatoid arthritis. Nanoscale 2020, 12, 8546–8562. [Google Scholar] [CrossRef]
  25. Busch, A.; Wegner, A.; Haversath, M.; Jäger, M. Knochenersatzmaterialien in der orthopädischen Chirurgie: Von der aktuellen Situation zu künftigen Entwicklungen. Z. Orthop. Unfall. 2021, 159, 304–313. [Google Scholar] [CrossRef]
  26. Oryan, A.; Kamali, A.; Moshiri, A.; Baghaban Eslaminejad, M. Role of Mesenchymal Stem Cells in Bone Regenerative Medicine: What Is the Evidence? Cells Tissues Organs 2017, 204, 59–83. [Google Scholar] [CrossRef]
  27. Miceli, V.; Bulati, M.; Iannolo, G.; Zito, G.; Gallo, A.; Conaldi, P.G. Therapeutic Properties of Mesenchymal Stromal/Stem Cells: The Need of Cell Priming for Cell-Free Therapies in Regenerative Medicine. Int. J. Mol. Sci. 2021, 22, 763. [Google Scholar] [CrossRef]
  28. Hayashi, K.; Tabata, Y. Preparation of stem cell aggregates with gelatin microspheres to enhance biological functions. Acta Biomater. 2011, 7, 2797–2803. [Google Scholar] [CrossRef] [Green Version]
  29. Ferreira, L.P.; Gaspar, V.M.; Mano, J.F. Bioinstructive microparticles for self-assembly of mesenchymal stem Cell-3D tumor spheroids. Biomaterials 2018, 185, 155–173. [Google Scholar] [CrossRef]
  30. Reddi, A.H. Interplay between bone morphogenetic proteins and cognate binding proteins in bone and cartilage development: Noggin, chordin and DAN. Arthritis Res. 2001, 3, 1–5. [Google Scholar] [CrossRef] [Green Version]
  31. Gazzerro, E.; Canalis, E. Bone morphogenetic proteins and their antagonists. Rev. Endocr. Metab. Disord. 2007, 7, 51–65. [Google Scholar] [CrossRef]
  32. Kwong, F.N.K.; Richardson, S.M.; Evans, C.H. Chordin knockdown enhances the osteogenic differentiation of human mesenchymal stem cells. Arthritis Res. Ther. 2008, 10, R65. [Google Scholar] [CrossRef] [Green Version]
  33. Wang, C.; Yuan, W.; Xiao, F.; Gan, Y.; Zhao, X.; Zhai, Z.; Zhao, X.; Zhao, C.; Cui, P.; Jin, T.; et al. Biscarbamate Cross-Linked Low-Molecular-Weight Polyethylenimine for Delivering Anti-chordin siRNA into Human Mesenchymal Stem Cells for Improving Bone Regeneration. Front. Pharmacol. 2017, 8, 572. [Google Scholar] [CrossRef] [Green Version]
  34. Hinkelmann, S.; Springwald, A.H.; Starke, A.; Kalwa, H.; Wölk, C.; Hacker, M.C.; Schulz-Siegmund, M. Microtissues from mesenchymal stem cells and siRNA-loaded cross-linked gelatin microparticles for bone regeneration. Mater. Today Bio 2022, 13, 100190. [Google Scholar] [CrossRef]
  35. Zhou, L.; Tan, G.; Tan, Y.; Wang, H.; Liao, J.; Ning, C. Biomimetic mineralization of anionic gelatin hydrogels: Effect of degree of methacrylation. RSC Adv. 2014, 4, 21997–22008. [Google Scholar] [CrossRef]
  36. Loth, T.; Hötzel, R.; Kascholke, C.; Anderegg, U.; Schulz-Siegmund, M.; Hacker, M.C. Gelatin-Based Biomaterial Engineering with Anhydride-Containing Oligomeric Cross-Linkers. Biomacromolecules 2014, 15, 2104–2118. [Google Scholar] [CrossRef]
  37. Kohn, C.; Klemens, J.M.; Kascholke, C.; Murthy, N.S.; Kohn, J.; Brandenburger, M.; Hacker, M.C. Dual-component collagenous peptide/reactive oligomer hydrogels as potential nerve guidance materials—From characterization to functionalization. Biomater. Sci. 2016, 4, 1605–1621. [Google Scholar] [CrossRef]
  38. Jacobi, A.; Rauh, J.; Bernstein, P.; Liebers, C.; Zou, X.; Stiehler, M. Comparative analysis of reference gene stability in human mesenchymal stromal cells during osteogenic differentiation. Biotechnol. Prog. 2013, 29, 1034–1042. [Google Scholar] [CrossRef]
  39. Lutter, A.-H.; Hempel, U.; Wolf-Brandstetter, C.; Garbe, A.I.; Goettsch, C.; Hofbauer, L.C.; Jessberger, R.; Dieter, P. A novel resorption assay for osteoclast functionality based on an osteoblast-derived native extracellular matrix. J. Cell. Biochem. 2010, 109, 1025–1032. [Google Scholar] [CrossRef]
  40. Schulze, S.; Wehrum, D.; Dieter, P.; Hempel, U. A supplement-free osteoclast-osteoblast co-culture for pre-clinical application. J. Cell Physiol. 2018, 233, 4391–4400. [Google Scholar] [CrossRef]
  41. Maxhimer, J.B.; Bradley, J.P.; Lee, J.C. Signaling pathways in osteogenesis and osteoclastogenesis: Lessons from cranial sutures and applications to regenerative medicine. Genes Dis. 2015, 2, 57–68. [Google Scholar] [CrossRef] [Green Version]
  42. Simonet, W.; Lacey, D.; Dunstan, C.; Kelley, M.; Chang, M.-S.; Lüthy, R.; Nguyen, H.; Wooden, S.; Bennett, L.; Boone, T.; et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density. Cell 1997, 89, 309–319. [Google Scholar] [CrossRef] [Green Version]
  43. Neto, M.D.; Oliveira, M.B.; Mano, J.F. Microparticles in Contact with Cells: From Carriers to Multifunctional Tissue Modulators. Trends Biotechnol. 2019, 37, 1011–1028. [Google Scholar] [CrossRef]
  44. Bratt-Leal, A.M.; Nguyen, A.H.; Hammersmith, K.A.; Singh, A.; McDevitt, T.C. A microparticle approach to morphogen delivery within pluripotent stem cell aggregates. Biomaterials 2013, 34, 7227–7235. [Google Scholar] [CrossRef] [Green Version]
  45. Kellner, K.; Liebsch, G.; Klimant, I.; Wolfbeis, O.S.; Blunk, T.; Schulz, M.B.; Göpferich, A. Determination of oxygen gradients in engineered tissue using a fluorescent sensor. Biotechnol. Bioeng. 2002, 80, 73–83. [Google Scholar] [CrossRef] [PubMed]
  46. Tajima, S.; Tabata, Y. Preparation of cell aggregates incorporating gelatin hydrogel microspheres containing bone morphogenic protein-2 with different degradabilities. J. Biomater. Sci. Polym. Ed. 2018, 29, 775–792. [Google Scholar] [CrossRef] [PubMed]
  47. Prins, H.-J.; Braat, A.K.; Gawlitta, D.; Dhert, W.J.; Egan, D.A.; Tijssen-Slump, E.; Yuan, H.; Coffer, P.J.; Rozemuller, H.; Martens, A.C. In vitro induction of alkaline phosphatase levels predicts in vivo bone forming capacity of human bone marrow stromal cells. Stem Cell Res. 2014, 12, 428–440. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Campodoni, E.; Dozio, S.M.; Panseri, S.; Montesi, M.; Tampieri, A.; Sandri, M. Mimicking Natural Microenvironments: Design of 3D-Aligned Hybrid Scaffold for Dentin Regeneration. Front. Bioeng. Biotechnol. 2020, 8, 836. [Google Scholar] [CrossRef]
  49. Kang, H.; Shih, Y.-R.V.; Hwang, Y.; Wen, C.; Rao, V.; Seo, T.; Varghese, S. Mineralized gelatin methacrylate-based matrices induce osteogenic differentiation of human induced pluripotent stem cells. Acta Biomater. 2014, 10, 4961–4970. [Google Scholar] [CrossRef] [Green Version]
  50. Wu, X.; Zhang, T.; Hoff, B.; Suvarnapathaki, S.; Lantigua, D.; McCarthy, C.; Wu, B.; Camci-Unal, G. Mineralized Hydrogels Induce Bone Regeneration in Critical Size Cranial Defects. Adv. Healthc. Mater. 2021, 10, 2001101. [Google Scholar] [CrossRef]
  51. Weiner, S. An Overview of Biomineralization Processes and the Problem of the Vital Effect; De Gruyter: Berlin, Germany, 2003; ISBN 9781501509346. [Google Scholar]
  52. Chen, Y.; Feng, Y.; Deveaux, J.G.; Masoud, M.A.; Chandra, F.S.; Chen, H.; Zhang, D.; Feng, L. Biomineralization Forming Process and Bio-inspired Nanomaterials for Biomedical Application: A Review. Minerals 2019, 9, 68. [Google Scholar] [CrossRef] [Green Version]
  53. Chang, Y.L.; Stanford, C.M.; Keller, J.C. Calcium and phosphate supplementation promotes bone cell mineralization: Implications for hydroxyapatite (HA)-enhanced bone formation. J. Biomed. Mater. Res. 2000, 52, 270–278. [Google Scholar] [CrossRef]
  54. Li, N.; Zhou, L.; Xie, W.; Zeng, D.; Cai, D.; Wang, H.; Zhou, C.; Wang, J.; Li, L. Alkaline phosphatase enzyme-induced biomineralization of chitosan scaffolds with enhanced osteogenesis for bone tissue engineering. Chem. Eng. J. 2019, 371, 618–630. [Google Scholar] [CrossRef]
  55. Öfkeli, F.; Demir, D.; Bölgen, N. Biomimetic mineralization of chitosan/gelatin cryogels and in vivo biocompatibility assessments for bone tissue engineering. J. Appl. Polym. Sci. 2021, 138, 50337. [Google Scholar] [CrossRef]
  56. Fortuna, R.; Anderson, H.C.; Carty, R.P.; Sajdera, S.W. Enzymatic characterization of the matrix vesicle alkaline phosphatase isolated from bovine fetal epiphyseal cartilage. Calcif. Tissue Int. 1980, 30, 217–225. [Google Scholar] [CrossRef]
  57. Holtz, K.M.; Kantrowitz, E.R. The mechanism of the alkaline phosphatase reaction: Insights from NMR, crystallography and site-specific mutagenesis. FEBS Lett. 1999, 462, 7–11. [Google Scholar] [CrossRef] [Green Version]
  58. D’Angelo, F.; Tiribuzi, R.; Armentano, I.; Kenny, J.M.; Martino, S.; Orlacchio, A. Mechanotransduction: Tuning Stem Cells Fate. JFB 2011, 2, 67–87. [Google Scholar] [CrossRef] [Green Version]
  59. Nakamura, T.; Nakamura-Takahashi, A.; Kasahara, M.; Yamaguchi, A.; Azuma, T. Tissue-nonspecific alkaline phosphatase promotes the osteogenic differentiation of osteoprogenitor cells. Biochem. Biophys. Res. Commun. 2020, 524, 702–709. [Google Scholar] [CrossRef]
  60. Narisawa, S.; Yadav, M.C.; Millán, J.L. In Vivo Overexpression of Tissue-Nonspecific Alkaline Phosphatase Increases Skeletal Mineralization and Affects the Phosphorylation Status of Osteopontin. J. Bone Miner. Res. 2013, 28, 1587–1598. [Google Scholar] [CrossRef] [Green Version]
  61. Brändström, H.; Björkman, T.; Ljunggren, Ö. Regulation of Osteoprotegerin Secretion from Primary Cultures of Human Bone Marrow Stromal Cells. Biochem. Biophys. Res. Commun. 2001, 280, 831–835. [Google Scholar] [CrossRef]
  62. Fuller, K.; Owens, J.M.; Jagger, C.J.; Wilson, A.; Moss, R.; Chambers, T.J. Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. J. Exp. Med. 1993, 178, 1733–1744. [Google Scholar] [CrossRef] [PubMed]
  63. Kong, Y.-Y.; Yoshida, H.; Sarosi, I.; Tan, H.-L.; Timms, E.; Capparelli, C.; Morony, S.; Oliveira-dos-Santos, A.J.; Van, G.; Itie, A.; et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999, 397, 315–323. [Google Scholar] [CrossRef] [PubMed]
  64. Birmingham, E.; Niebur, G.L.; McHugh, P.E.; Shaw, G.; Barry, F.P.; McNamara, L.M. Osteogenic differentiation of mesenchymal stem cells is regulated by osteocyte and osteoblast cells in a simplified bone niche. Eur. Cell. Mater. 2012, 23, 13–27. [Google Scholar] [CrossRef] [PubMed]
  65. Hofbauer, L.C.; Dunstan, C.R.; Spelsberg, T.C.; Riggs, B.; Khosla, S. Osteoprotegerin Production by Human Osteoblast Lineage Cells Is Stimulated by Vitamin D, Bone Morphogenetic Protein-2, and Cytokines. Biochem. Biophys. Res. Commun. 1998, 250, 776–781. [Google Scholar] [CrossRef]
  66. Granero-Moltó, F.; Weis, J.A.; Miga, M.I.; Landis, B.; Myers, T.J.; O’Rear, L.; Longobardi, L.; Jansen, E.D.; Mortlock, D.P.; Spagnoli, A. Regenerative Effects of Transplanted Mesenchymal Stem Cells in Fracture Healing. Stem Cells 2009, 27, 1887–1898. [Google Scholar] [CrossRef] [Green Version]
  67. Senior, J.H.; Trimble, K.R.; Maskiewicz, R. Interaction of positively-charged liposomes with blood: Implications for their application in vivo. Biochim. Biophys. Acta (BBA)-Biomembr. 1991, 1070, 173–179. [Google Scholar] [CrossRef]
  68. Jahnová, E.; Ferenčík, M.; Nyulassy, Š.; Devínsky, F.; Lacko, I. Amphiphilic detergents inhibit production of IgG and IgM by human peripheral blood mononuclear cells. Immunol. Lett. 1993, 39, 71–75. [Google Scholar] [CrossRef]
  69. Suhorutsenko, J.; Oskolkov, N.; Arukuusk, P.; Kurrikoff, K.; Eriste, E.; Copolovici, D.-M.; Langel, U. Cell-penetrating peptides, PepFects, show no evidence of toxicity and immunogenicity in vitro and in vivo. Bioconjug. Chem. 2011, 22, 2255–2262. [Google Scholar] [CrossRef]
  70. Khare, P.; Dave, K.M.; Kamte, Y.S.; Manoharan, M.A.; O’Donnell, L.A.; Manickam, D.S. Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells. AAPS J. 2021, 24, 8. [Google Scholar] [CrossRef]
  71. Zhao, Y.; Li, Z.; Jiang, Y.; Liu, H.; Feng, Y.; Wang, Z.; Liu, H.; Wang, J.; Yang, B.; Lin, Q. Bioinspired mineral hydrogels as nanocomposite scaffolds for the promotion of osteogenic marker expression and the induction of bone regeneration in osteoporosis. Acta Biomater. 2020, 113, 614–626. [Google Scholar] [CrossRef]
Pharmaceutics 14 00548 g001 550
Figure 1. Chordin and alkaline phosphatase (ALP) expression in microtissues assembled from siRNA-loaded cGM and hMSC after 4 days in an osteogenic medium with or without BMP-2 (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA). Statistically significant differences (p < 0.05) are indicated with (*).
Figure 1. Chordin and alkaline phosphatase (ALP) expression in microtissues assembled from siRNA-loaded cGM and hMSC after 4 days in an osteogenic medium with or without BMP-2 (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA). Statistically significant differences (p < 0.05) are indicated with (*).
Pharmaceutics 14 00548 g001
Pharmaceutics 14 00548 g002 550
Figure 2. (a) ALP activity after 7 days, and mineralization after (b) 14 and (c) 21 in microtissues assembled from siRNA-loaded cGM and hMSC cultured in osteogenic medium with or without BMP-2 (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA). Statistically significant differences (p < 0.05) are indicated with (*).
Figure 2. (a) ALP activity after 7 days, and mineralization after (b) 14 and (c) 21 in microtissues assembled from siRNA-loaded cGM and hMSC cultured in osteogenic medium with or without BMP-2 (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA). Statistically significant differences (p < 0.05) are indicated with (*).
Pharmaceutics 14 00548 g002
Pharmaceutics 14 00548 g003 550
Figure 3. DNA content after 7, 14, and 21 days in microtissues assembled from siRNA-loaded cGM and hMSC cultured in osteogenic medium with or without BMP-2 (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA).
Figure 3. DNA content after 7, 14, and 21 days in microtissues assembled from siRNA-loaded cGM and hMSC cultured in osteogenic medium with or without BMP-2 (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA).
Pharmaceutics 14 00548 g003
Pharmaceutics 14 00548 g004 550
Figure 4. Representative images of hydroxyapatite (HA) formation (OsteoImage staining) in microtissues from hMSC (green: HA, red: actin cytoskeleton) with or without chordin siRNA by confocal laser scanning microscopy (HA formations in the interspace of agglomerated cGMs are highlighted by white arrows). Stem cells were cultivated in an osteogenic medium (OM) with or without BMP-2 for 21 days. Scale bar represents 500 µm.
Figure 4. Representative images of hydroxyapatite (HA) formation (OsteoImage staining) in microtissues from hMSC (green: HA, red: actin cytoskeleton) with or without chordin siRNA by confocal laser scanning microscopy (HA formations in the interspace of agglomerated cGMs are highlighted by white arrows). Stem cells were cultivated in an osteogenic medium (OM) with or without BMP-2 for 21 days. Scale bar represents 500 µm.
Pharmaceutics 14 00548 g004
Pharmaceutics 14 00548 g005 550
Figure 5. (a) Alizarin red staining (ARS) and (b) OsteoImage staining of cryosections (10–20 µm) of mineralized microtissues with and without siRNA or/and BMP-2 after 21 days in osteogenic medium (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA). Scale bar represents 50 µm.
Figure 5. (a) Alizarin red staining (ARS) and (b) OsteoImage staining of cryosections (10–20 µm) of mineralized microtissues with and without siRNA or/and BMP-2 after 21 days in osteogenic medium (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA). Scale bar represents 50 µm.
Pharmaceutics 14 00548 g005
Pharmaceutics 14 00548 g006 550
Figure 6. Close-up of cGM in the early and late mineralization phase stained with Alizarin Red staining (ARS) or OsteoImage (HA). The mineralized areas have been marked with dashed lines in green for the inner mineralization zone, in blue for the outer mineralization zone, and orange for completely mineralized particles.
Figure 6. Close-up of cGM in the early and late mineralization phase stained with Alizarin Red staining (ARS) or OsteoImage (HA). The mineralized areas have been marked with dashed lines in green for the inner mineralization zone, in blue for the outer mineralization zone, and orange for completely mineralized particles.
Pharmaceutics 14 00548 g006
Pharmaceutics 14 00548 g007 550
Figure 7. Ca/P ratio after 14 and 21 days (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA) in microtissues from siRNA-loaded cross-linked gelatin microparticles (cGM) and hMSC in an osteogenic medium (OM) with or without BMP-2 (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA). Dashed line: stoichiometric Ca/P ratio of pure hydroxyapatite (1.67).
Figure 7. Ca/P ratio after 14 and 21 days (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA) in microtissues from siRNA-loaded cross-linked gelatin microparticles (cGM) and hMSC in an osteogenic medium (OM) with or without BMP-2 (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA). Dashed line: stoichiometric Ca/P ratio of pure hydroxyapatite (1.67).
Pharmaceutics 14 00548 g007
Pharmaceutics 14 00548 g008 550
Figure 8. (a) Graphical outline of the experimental procedure: chordin siRNA-loaded microtissues were stimulated in OM or OM+BMP-2 for 7 days and transferred to a supplement-free co-culture system of hMSC (human mesenchymal stem cells) and hPBMC (human peripheral blood mononuclear cells) seeded on a decellularized mineralized matrix. hPBMC and hMSC were cultivated together with pre-differentiated microtissues in a supplement-free culture medium for 14 days. (b) ALP and TRAP activity were analyzed after 14 days of supplement-free co-culture (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA). Statistically significant differences (p < 0.05) are indicated with (*).
Figure 8. (a) Graphical outline of the experimental procedure: chordin siRNA-loaded microtissues were stimulated in OM or OM+BMP-2 for 7 days and transferred to a supplement-free co-culture system of hMSC (human mesenchymal stem cells) and hPBMC (human peripheral blood mononuclear cells) seeded on a decellularized mineralized matrix. hPBMC and hMSC were cultivated together with pre-differentiated microtissues in a supplement-free culture medium for 14 days. (b) ALP and TRAP activity were analyzed after 14 days of supplement-free co-culture (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA). Statistically significant differences (p < 0.05) are indicated with (*).
Pharmaceutics 14 00548 g008
Pharmaceutics 14 00548 g009 550
Figure 9. Osteoprotegerin (OPG) in the supernatant during supplement-free co-culture of hMSC (human mesenchymal stem cells) and hPBMC (human peripheral blood mononuclear cells) seeded on a decellularized mineralized matrix with pre-differentiated microtissues (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA). Statistically significant differences (p < 0.05) between ctr and chrd are indicated with (#), between nc and chrd with (§).
Figure 9. Osteoprotegerin (OPG) in the supernatant during supplement-free co-culture of hMSC (human mesenchymal stem cells) and hPBMC (human peripheral blood mononuclear cells) seeded on a decellularized mineralized matrix with pre-differentiated microtissues (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA). Statistically significant differences (p < 0.05) between ctr and chrd are indicated with (#), between nc and chrd with (§).
Pharmaceutics 14 00548 g009
Table
Table 1. TaqMan™ Gene Expression assays.
Table 1. TaqMan™ Gene Expression assays.
SymbolGene NameAssay ID
ALPLAlkaline phosphatase activity, liver/bone/kidneyHS01029144_m1
CHRDChordinHS00415315_m1
RPLP060S acidic ribosomal protein P0HS99999902_m1
Table
Table 2. Average particle size of dry and swollen particles.
Table 2. Average particle size of dry and swollen particles.
Particle StateD [4,3]
dry particles79.15 ± 10.68 µm
swollen particles137.67 ± 18.77 µm
Table
Table 3. Proliferation rates (increase DNA in ng per day) in microtissues from siRNA-loaded cGM and hMSC in an osteogenic medium with or without BMP-2 (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA).
Table 3. Proliferation rates (increase DNA in ng per day) in microtissues from siRNA-loaded cGM and hMSC in an osteogenic medium with or without BMP-2 (ctr: non-treated control, nc: non-coding siRNA, chrd: chordin siRNA).
SampleProliferation Rate ng/DayR2
ctr2.660.9938
nc4.520.9837
chrd3.210.9953
ctr+BMP-20.610.2336
nc+BMP-22.100.7228
chrd+BMP-20.700.972
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Hinkelmann, S.; Springwald, A.H.; Schulze, S.; Hempel, U.; Mitrach, F.; Wölk, C.; Hacker, M.C.; Schulz-Siegmund, M. Mineralizing Gelatin Microparticles as Cell Carrier and Drug Delivery System for siRNA for Bone Tissue Engineering. Pharmaceutics 2022, 14, 548. https://doi.org/10.3390/pharmaceutics14030548

AMA Style

Hinkelmann S, Springwald AH, Schulze S, Hempel U, Mitrach F, Wölk C, Hacker MC, Schulz-Siegmund M. Mineralizing Gelatin Microparticles as Cell Carrier and Drug Delivery System for siRNA for Bone Tissue Engineering. Pharmaceutics. 2022; 14(3):548. https://doi.org/10.3390/pharmaceutics14030548

Chicago/Turabian Style

Hinkelmann, Sandra, Alexandra H. Springwald, Sabine Schulze, Ute Hempel, Franziska Mitrach, Christian Wölk, Michael C. Hacker, and Michaela Schulz-Siegmund. 2022. "Mineralizing Gelatin Microparticles as Cell Carrier and Drug Delivery System for siRNA for Bone Tissue Engineering" Pharmaceutics 14, no. 3: 548. https://doi.org/10.3390/pharmaceutics14030548

APA Style

Hinkelmann, S., Springwald, A. H., Schulze, S., Hempel, U., Mitrach, F., Wölk, C., Hacker, M. C., & Schulz-Siegmund, M. (2022). Mineralizing Gelatin Microparticles as Cell Carrier and Drug Delivery System for siRNA for Bone Tissue Engineering. Pharmaceutics, 14(3), 548. https://doi.org/10.3390/pharmaceutics14030548

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop